Jobs / United States / Astrazeneca Pharmaceuticals Lp
Director, Oncology Clinical Intelligence & RWE Strategy
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Cambridge Kendall SQ - MA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
We're building a connected, end-to-end Enterprise AI engine - uniting data foundations, AI technology, process reinvention, and business-facing AI to accelerate results across the whole value chain. Success depends on being exceptional connectors : you'll actively leverage existing capabilities, celebrate and promote reuse, export breakthrough ideas across geographies and functions, and obsess over scaling impact rather than building in isolation. If you thrive in high-collaboration environments where your role is to turn complex, cross-functional problems into reusable, enterprise-wide capabilities - and where the measure of success is adoption and scale, not just innovation - you'll have the platform (and sponsorship) to make it real. Introduction to role: Are you ready to turn complex, multimodal data into decisive actions that shape the future of oncology ? This role leads a connected evidence strategy spanning R&D through patient care, where your decisions influence trials, filings, and access strategies that reach patients faster. You will help power an enterprise-scale AI and data engine by being an exceptional connector leveraging existing capabilities, scaling what works, and exporting breakthrough ideas across teams and geographies. Can you see yourself guiding senior stakeholders through complex trade-offs to deliver impact at scale ? You will own the end- to- end evidence agenda for an on c ology therapeutic area , aligning it to the highest-priority scientific, medical, and business needs across the lifecycle. By harnessing the PH3ID Intelligence Foundation and rich multimodal assets, you will translate signals into intelligence that advances portfolio investment decisions, strengthens regulatory packages, and sharpens commercial positioning. You will work at the interface of Translational Science, Clinical Development, and Market Access leading without direct authority in a matrixed environment. Join a team dedicated to building AI-enabled evidence that persists and extends across use cases, helping a fast-growing therapeutic area set the pace for the portfolio. Accountabilities: End-to-End Evidence Strategy : Own the clinical intelligence and real-world evidence strategy from R&D through patient care, building a clear roadmap tied to the most critical scientific, medical, and business priorities across development, regulatory, and market access. Evidence Gap Prioritization: Define and rank the evidence gaps that matter most, informing PH3ID, trial design, external control arm strategies, and subpopulation discovery to accelerate confident decisions. Translational and Clinical Partnership: Partner with Translational Science and Clinical Development to integrate genomics, imaging, digital endpoints, and pathology AI into strategies for patient stratification and biomarker-driven development. AI-Enabled Hematology Methods : Advance AI-driven approaches including tumor dynamics forecasting, prognostic risk adjustment, trial simulation, and transportability analyses to de-risk and optimize clinical programs. Integrated Insight Generation: Convert internal and competitor trial data, together with real-world data, into actionable insight on standard of care, patient journeys, unmet need, and competitive positioning that guides development and access strategies. Stakeholder Influence and Alignment: Influence Global Product Teams, matrix partners, and external data collaborators to ensure evidence outputs are both methodologically rigorous and strategically relevant. Compounding Intelligence Foundation : Build an oncology therapeutic area specific intelligence that persists and grows within the PH3ID Intelligence Foundation